Disease control is the primary clinical objective, and Lifyorli plus weekly nab-paclitaxel prolongs time on therapy without progression while generally preserving day-to-day function through tolerable ...

In this study, researchers aimed to investigate whether discontinuing premedications after 2 doses of paclitaxel is safe and feasible in some breast cancer patients.

BERLIN — The combination of pembrolizumab with weekly paclitaxel, with or without bevacizumab, leads to significant improvements in survival outcomes in patients with platinum-resistant recurrent ...